866-997-4948(US-Canada Toll Free)

Squamous Non-Small Cell Lung Cancer - Pipeline Review, H1 2014

Published By :

Global Markets Direct

Published Date : Feb 2014

Category :

Cancer

No. of Pages : 84 Pages

Squamous Non-Small Cell Lung Cancer - Pipeline Review, H1 2014

Summary

Global Markets Directs, Squamous Non-Small Cell Lung Cancer - Pipeline Review, H1 2014, provides an overview of the Squamous Non-Small Cell Lung Cancers therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Squamous Non-Small Cell Lung Cancer, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Squamous Non-Small Cell Lung Cancer and special features on late-stage and discontinued projects.

Global Markets Directs report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Directs proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Directs team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Squamous Non-Small Cell Lung Cancer
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in the therapeutics development for Squamous Non-Small Cell Lung Cancer and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects
- A review of the Squamous Non-Small Cell Lung Cancer products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Squamous Non-Small Cell Lung Cancer pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Squamous Non-Small Cell Lung Cancer
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Squamous Non-Small Cell Lung Cancer pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Contents
Table of Contents 2
List of Tables 5
List of Figures 5
Introduction 6
Global Markets Direct Report Coverage 6
Squamous Non-Small Cell Lung Cancer Overview 7
Therapeutics Development 8
Pipeline Products for Squamous Non-Small Cell Lung Cancer - Overview 8
Pipeline Products for Squamous Non-Small Cell Lung Cancer - Comparative Analysis 9
Squamous Non-Small Cell Lung Cancer - Therapeutics under Development by Companies 10
Squamous Non-Small Cell Lung Cancer - Pipeline Products Glance 12
Late Stage Products 12
Clinical Stage Products 13
Early Stage Products 14
Squamous Non-Small Cell Lung Cancer - Products under Development by Companies 15
Squamous Non-Small Cell Lung Cancer - Companies Involved in Therapeutics Development 16
Bristol-Myers Squibb Company 16
Boehringer Ingelheim GmbH 17
F. Hoffmann-La Roche Ltd. 18
AstraZeneca PLC 19
Eli Lilly and Company 20
Novartis AG 21
Eisai Co., Ltd. 22
Ascenta Therapeutics, Inc. 23
Five Prime Therapeutics, Inc. 24
Immunocore Limited 25
Squamous Non-Small Cell Lung Cancer - Therapeutics Assessment 26
Assessment by Monotherapy Products 26
Assessment by Target 27
Assessment by Mechanism of Action 30
Assessment by Route of Administration 33
Assessment by Molecule Type 35
Drug Profiles 37
ipilimumab - Drug Profile 37
Product Description 37
Mechanism of Action 37
R&D Progress 37
necitumumab - Drug Profile 40
Product Description 40
Mechanism of Action 40
R&D Progress 40
lenvatinib - Drug Profile 42
Product Description 42
Mechanism of Action 42
R&D Progress 42
onartuzumab - Drug Profile 45
Product Description 45
Mechanism of Action 45
R&D Progress 45
LY-2606368 - Drug Profile 48
Product Description 48
Mechanism of Action 48
R&D Progress 48
nintedanib - Drug Profile 49
Product Description 49
Mechanism of Action 49
R&D Progress 49
AZD-4547 - Drug Profile 51
Product Description 51
Mechanism of Action 51
R&D Progress 51
buparlisib hydrochloride - Drug Profile 52
Product Description 52
Mechanism of Action 52
R&D Progress 52
FP-1039 - Drug Profile 55
Product Description 55
Mechanism of Action 55
R&D Progress 55
AT-406 - Drug Profile 57
Product Description 57
Mechanism of Action 57
R&D Progress 57
AZD-8186 - Drug Profile 60
Product Description 60
Mechanism of Action 60
R&D Progress 60
ImmTAC Targeting MAGE A3 - Drug Profile 61
Product Description 61
Mechanism of Action 61
R&D Progress 61
Squamous Non-Small Cell Lung Cancer - Recent Pipeline Updates 62
Squamous Non-Small Cell Lung Cancer - Dormant Projects 74
Squamous Non-Small Cell Lung Cancer - Discontinued Products 75
Squamous Non-Small Cell Lung Cancer - Product Development Milestones 76
Featured News & Press Releases 76
Jan 16, 2014: Biothera Research Shows Potential for Treating Imprime PGG Biomarker-Negative Cancer Patients 76
Aug 13, 2013: Eli Lilly and Company's Phase III study of necitumumab meets primary endpoint 77
Jun 04, 2013: Debiopharm Announces Additional Phase I Clinical Trial Evaluating Debio 1143 Combined With Chemotherapies For Patients With Selected Solid Malignancies 77
May 23, 2013: OncoGenex Pharma Announces Plans For Initiation Of Cedar Clinical Trial Evaluating OGX-427 In Combination With Chemotherapy In Advanced Squamous Cell Lung Cancer 78
May 15, 2013: Boehringer Ingelheim To Present Six Abstracts For Nintedanib At ASCO 2013 78
Apr 08, 2013: Ariad Pharma Presents New Preclinical Data On Ponatinib At AACR Annual Meeting 2013 79
Mar 28, 2013: Oncolytics Biotech Meets Primary Overall Statistical Endpoint In US Phase II Study Of Reolysin In Squamous Cell Lung Cancer 80
Feb 08, 2013: Oncolytics Biotech Announces Additional Positive Reolysin Clinical Trial Data From Phase II Study In Squamous Cell Carcinoma Of Lung 81
Sep 13, 2012: Oncolytics Biotech Meets Primary Endpoint For First Stage Of US Phase II Squamous Cell Lung Cancer Clinical Trial 81
Oct 29, 2010: Novotech Initiates Three Phase Ib Cancer Trials With Oncomed Pharma's Humanized Monoclonal Antibody Product In Australia And New Zealand 82
Appendix 83
Methodology 83
Coverage 83
Secondary Research 83
Primary Research 83
Expert Panel Validation 83
Contact Us 84
Disclaimer 84

List of Table

List of Tables
Number of Products under Development for Squamous Non-Small Cell Lung Cancer, H1 2014 8
Number of Products under Development for Squamous Non-Small Cell Lung Cancer - Comparative Analysis, H1 2014 9
Number of Products under Development by Companies, H1 2014 11
Comparative Analysis by Late Stage Development, H1 2014 12
Comparative Analysis by Clinical Stage Development, H1 2014 13
Comparative Analysis by Early Stage Development, H1 2014 14
Products under Development by Companies, H1 2014 15
Squamous Non-Small Cell Lung Cancer - Pipeline by Bristol-Myers Squibb Company, H1 2014 16
Squamous Non-Small Cell Lung Cancer - Pipeline by Boehringer Ingelheim GmbH, H1 2014 17
Squamous Non-Small Cell Lung Cancer - Pipeline by F. Hoffmann-La Roche Ltd., H1 2014 18
Squamous Non-Small Cell Lung Cancer - Pipeline by AstraZeneca PLC, H1 2014 19
Squamous Non-Small Cell Lung Cancer - Pipeline by Eli Lilly and Company, H1 2014 20
Squamous Non-Small Cell Lung Cancer - Pipeline by Novartis AG, H1 2014 21
Squamous Non-Small Cell Lung Cancer - Pipeline by Eisai Co., Ltd., H1 2014 22
Squamous Non-Small Cell Lung Cancer - Pipeline by Ascenta Therapeutics, Inc., H1 2014 23
Squamous Non-Small Cell Lung Cancer - Pipeline by Five Prime Therapeutics, Inc., H1 2014 24
Squamous Non-Small Cell Lung Cancer - Pipeline by Immunocore Limited, H1 2014 25
Assessment by Monotherapy Products, H1 2014 26
Number of Products by Stage and Target, H1 2014 29
Number of Products by Stage and Mechanism of Action, H1 2014 32
Number of Products by Stage and Route of Administration, H1 2014 34
Number of Products by Stage and Molecule Type, H1 2014 36
Squamous Non-Small Cell Lung Cancer Therapeutics - Recent Pipeline Updates, H1 2014 62
Squamous Non-Small Cell Lung Cancer - Dormant Projects, H1 2014 74
Squamous Non-Small Cell Lung Cancer - Discontinued Products, H1 2014 75

List of Chart

List of Figures
Number of Products under Development for Squamous Non-Small Cell Lung Cancer, H1 2014 8
Number of Products under Development for Squamous Non-Small Cell Lung Cancer - Comparative Analysis, H1 2014 9
Number of Products under Development by Companies, H1 2014 10
Comparative Analysis by Clinical Stage Development, H1 2014 13
Assessment by Monotherapy Products, H1 2014 26
Number of Products by Top 10 Target, H1 2014 27
Number of Products by Stage and Top 10 Target, H1 2014 28
Number of Products by Top 10 Mechanism of Action, H1 2014 30
Number of Products by Stage and Top 10 Mechanism of Action, H1 2014 31
Number of Products by Top 10 Route of Administration, H1 2014 33
Number of Products by Stage and Top 10 Route of Administration, H1 2014 34
Number of Products by Top 10 Molecule Type, H1 2014 35
Number of Products by Stage and Top 10 Molecule Type, H1 2014 36

Make an enquiry before buying this Report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title *
  • Company *
  • Phone No. * (Pls. Affix Country Code)
  • Message
  • Security Code *